Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000695755 | SCV000824273 | pathogenic | Gorlin syndrome; Medulloblastoma | 2018-08-23 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in SUFU are known to be pathogenic (PMID: 22508808, 25403219). This variant has not been reported in the literature in individuals with SUFU-related disease. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Arg299Leufs*16) in the SUFU gene. It is expected to result in an absent or disrupted protein product. |
Prevention |
RCV004737958 | SCV005362355 | likely pathogenic | SUFU-related disorder | 2024-09-20 | no assertion criteria provided | clinical testing | The SUFU c.895_896insTGTGT variant is predicted to result in a frameshift and premature protein termination (p.Arg299Leufs*16). To our knowledge, this variant has not been reported in the literature. This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/573948/). Frameshift variants in SUFU are expected to be pathogenic. This variant is interpreted as likely pathogenic. |